Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Non-Current Deffered Revenue (2020 - 2023)

Historic Non-Current Deffered Revenue for Janux Therapeutics (JANX) over the last 4 years, with Q2 2023 value amounting to $307000.0.

  • Janux Therapeutics' Non-Current Deffered Revenue fell 9419.55% to $307000.0 in Q2 2023 from the same period last year, while for Jun 2023 it was $307000.0, marking a year-over-year decrease of 9419.55%. This contributed to the annual value of $2.2 million for FY2022, which is 21728.57% up from last year.
  • Per Janux Therapeutics' latest filing, its Non-Current Deffered Revenue stood at $307000.0 for Q2 2023, which was down 9419.55% from $1.4 million recorded in Q1 2023.
  • Janux Therapeutics' 5-year Non-Current Deffered Revenue high stood at $6.0 million for Q4 2020, and its period low was $307000.0 during Q2 2023.
  • Its 4-year average for Non-Current Deffered Revenue is $2.7 million, with a median of $2.2 million in 2022.
  • In the last 5 years, Janux Therapeutics' Non-Current Deffered Revenue surged by 21728.57% in 2022 and then plummeted by 9419.55% in 2023.
  • Quarter analysis of 4 years shows Janux Therapeutics' Non-Current Deffered Revenue stood at $6.0 million in 2020, then tumbled by 88.43% to $700000.0 in 2021, then surged by 217.29% to $2.2 million in 2022, then plummeted by 86.18% to $307000.0 in 2023.
  • Its Non-Current Deffered Revenue was $307000.0 in Q2 2023, compared to $1.4 million in Q1 2023 and $2.2 million in Q4 2022.